Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Monte Rosa Therapeutics Q3 EPS $(0.70) Beats $(0.72) Estimate; Cash, Cash Equivalents, Restricted Cash, And Marketable Securities Of $183M Sufficient To Fund Planned Operations And Capital Expenditures Into 1H Of 2026

Author: Benzinga Newsdesk | November 09, 2023 08:38am
Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(0.72) by 2.78 percent. This is a 20.69 percent decrease over losses of $(0.58) per share from the same period last year.

Posted In: GLUE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist